Transforming growth factor beta receptor complex (TGFBR complex) (TGFBR complex)

The Transforming growth factor beta (TGF-beta) receptor complex is a transmembrane heterotetramer typically composed of two Type I (TGFBR1/ALK5) and two Type II (TGFBR2) serine/threonine kinase receptors (UniProt: P36897, P37173). Upon binding of TGF-beta ligands, the Type II receptor phosphorylates the Type I receptor, which subsequently activates the canonical SMAD2/3 signaling pathway to regulate gene transcription (PubMed: 28944915). This complex plays a dual role in human physiology; it acts as a potent growth inhibitor and tumor suppressor in normal tissues, but is frequently co-opted by advanced cancers to promote metastasis, angiogenesis, and immune evasion (PubMed: 30622371). Additionally, the complex is a master regulator of the extracellular matrix, making it a primary driver of fibrotic diseases in the liver, lungs, and kidneys (PubMed: 22633440). Therapeutic interventions include small-molecule kinase inhibitors like galunisertib and monoclonal antibodies like fresolimumab, which aim to disrupt these pathological processes. However, drug development is complicated by the pathway's essential role in cardiovascular homeostasis and tissue repair, leading to potential safety concerns such as valvulopathy and skin lesions (PubMed: 25135992).

Other names

TGF-beta receptor complexTGF-beta signaling complexTGFBR1/TGFBR2 complexTbetaR complexALK5/TGFBR2 complex

Inhibition of TGF-beta signaling through small molecule antagonism of the TGFBR1 (ALK5) kinase domain, neutralization of TGF-beta ligands by monoclonal antibodies, or the use of ligand traps and bifunctional fusion proteins to sequester ligands.